These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 33459728)

  • 21. Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with Nasal Polyps.
    Peters AT; Han JK; Hellings P; Heffler E; Gevaert P; Bachert C; Xu Y; Chuang CC; Neupane B; Msihid J; Mannent LP; Guyot P; Kamat S
    J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2461-2471.e5. PubMed ID: 33548517
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study.
    Gevaert P; Saenz R; Corren J; Han JK; Mullol J; Lee SE; Ow RA; Zhao R; Howard M; Wong K; Islam L; Ligueros-Saylan M; Omachi TA; Bachert C
    J Allergy Clin Immunol; 2022 Mar; 149(3):957-965.e3. PubMed ID: 34530020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Omalizumab Treatment in Uncontrolled Asthma and CRSwNP Patients, with Previous Endoscopic Sinus Surgery, to Improve Quality of Life and Endoscopic Outcomes: a Two-Year Real-Life Study.
    Maza-Solano J; Callejon-Leblic A; Martin-Jimenez D; Moreno-Luna R; Gonzalez-Garcia J; Cuvillo A; Sanchez-Gomez S
    Curr Allergy Asthma Rep; 2023 Oct; 23(10):555-566. PubMed ID: 37644255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Olfactory Outcomes With Dupilumab in Chronic Rhinosinusitis With Nasal Polyps.
    Mullol J; Bachert C; Amin N; Desrosiers M; Hellings PW; Han JK; Jankowski R; Vodicka J; Gevaert P; Daizadeh N; Khan AH; Kamat S; Patel N; Graham NMH; Ruddy M; Staudinger H; Mannent LP
    J Allergy Clin Immunol Pract; 2022 Apr; 10(4):1086-1095.e5. PubMed ID: 34628065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-Life Experience of Monoclonal Antibody Treatments in Chronic Rhinosinusitis with Nasal Polyposis.
    Meier EC; Schmid-Grendelmeier P; Steiner UC; Soyka MB
    Int Arch Allergy Immunol; 2021; 182(8):736-743. PubMed ID: 33756474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biologic Therapy in Pediatric Chronic Rhinosinusitis: A Systematic Review.
    Rahavi-Ezabadi S; Zhou S; Lee SE; Ference E; Magit A; Leuin S; Mohamed K; Rezaei N; Patel VA
    Otolaryngol Head Neck Surg; 2024 Jul; 171(1):35-44. PubMed ID: 38488239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of Omalizumab Treatment in Patients With Recalcitrant Nasal Polyposis and Mild Asthma: A Multicenter Retrospective Study.
    Armengot-Carceller M; Gómez-Gómez MJ; García-Navalón C; Doménech-Campos E; Muñoz-Fernández N; Miguel AG; Marco-Algarra J; Palop-Cervera M; Piñero AG
    Am J Rhinol Allergy; 2021 Jul; 35(4):516-524. PubMed ID: 33153272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Defining the Efficacy of Omalizumab in Nasal Polyposis: A POLYP 1 and POLYP 2 Subgroup Analysis.
    Damask C; Chen M; Holweg CTJ; Yoo B; Millette LA; Franzese C
    Am J Rhinol Allergy; 2022 Jan; 36(1):135-141. PubMed ID: 34382434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Switching of biological therapy to dupilumab in comorbid patients with severe asthma and CRSwNP.
    Rosso C; De Corso E; Conti V; Nitro L; Saibene AM; Parazzini E; Rinaldo R; De Pascalis S; Arnone F; Centanni S; Montuori C; D'Auria LM; Felisati G; Pipolo C
    Eur Arch Otorhinolaryngol; 2024 Jun; 281(6):3017-3023. PubMed ID: 38347197
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dupilumab: A Review in Chronic Rhinosinusitis with Nasal Polyps.
    Hoy SM
    Drugs; 2020 May; 80(7):711-717. PubMed ID: 32240527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis.
    Oykhman P; Paramo FA; Bousquet J; Kennedy DW; Brignardello-Petersen R; Chu DK
    J Allergy Clin Immunol; 2022 Apr; 149(4):1286-1295. PubMed ID: 34543652
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluating enrollment and outcome criteria in trials of biologics for chronic rhinosinusitis with nasal polyps.
    Borish L; Cohen NA; Chupp G; Hopkins C; Wagenmann M; Sousa AR; Smith SG; Silver J; Yang S; Mayer B; Yancey SW; Chan RH; Fokkens W
    Ann Allergy Asthma Immunol; 2022 Aug; 129(2):160-168. PubMed ID: 35398492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The relationship of sinus opacification, olfaction and dupilumab efficacy in patients with CRSwNP.
    Lee SE; Amin N; Mannent LP; Bachert C; Gross G; Cho SH; Praestgaard A; Siddiqui S; Nash S; Kamat S; Khan AH; Jacob Nara JA
    Rhinology; 2023 Dec; 61(6):531-540. PubMed ID: 37453138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dupilumab in CRSwNP: Responder Analysis Using Clinically Meaningful Efficacy Outcome Thresholds.
    Chuang CC; Guillemin I; Bachert C; Lee SE; Hellings PW; Fokkens WJ; Duverger N; Fan C; Daizadeh N; Amin N; Mannent LP; Khan AH; Kamat S
    Laryngoscope; 2022 Feb; 132(2):259-264. PubMed ID: 34817082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biologics for chronic rhinosinusitis with nasal polyps.
    Bachert C; Zhang N; Cavaliere C; Weiping W; Gevaert E; Krysko O
    J Allergy Clin Immunol; 2020 Mar; 145(3):725-739. PubMed ID: 32145872
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is generative pre-trained transformer artificial intelligence (Chat-GPT) a reliable tool for guidelines synthesis? A preliminary evaluation for biologic CRSwNP therapy.
    Maniaci A; Saibene AM; Calvo-Henriquez C; Vaira L; Radulesco T; Michel J; Chiesa-Estomba C; Sowerby L; Lobo Duro D; Mayo-Yanez M; Maza-Solano J; Lechien JR; La Mantia I; Cocuzza S
    Eur Arch Otorhinolaryngol; 2024 Apr; 281(4):2167-2173. PubMed ID: 38329526
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic Rhinosinusitis with Nasal Polyps: Targeting IgE with Anti-IgE Omalizumab Therapy.
    Kariyawasam HH; James LK
    Drug Des Devel Ther; 2020; 14():5483-5494. PubMed ID: 33328726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status.
    Fujieda S; Matsune S; Takeno S; Ohta N; Asako M; Bachert C; Inoue T; Takahashi Y; Fujita H; Deniz Y; Rowe P; Ortiz B; Li Y; Mannent LP
    Allergy; 2022 Jan; 77(1):186-196. PubMed ID: 33993501
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Role of Biologics in Chronic Rhinosinusitis With Nasal Polyps.
    Patel GB; Peters AT
    Ear Nose Throat J; 2021 Jan; 100(1):44-47. PubMed ID: 33035132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study.
    Detoraki A; Tremante E; D'Amato M; Calabrese C; Casella C; Maniscalco M; Poto R; Brancaccio R; Boccia M; Martino M; Imperatore C; Spadaro G
    Ther Adv Respir Dis; 2021; 15():17534666211009398. PubMed ID: 33910399
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.